Information  X 
Enter a valid email address

Diaceutics PLC (DXRX)

  Print   

Tuesday 04 May, 2021

Diaceutics PLC

Sale of Shares and Director/PDMR Shareholding

RNS Number : 5098X
Diaceutics PLC
04 May 2021
 

 

 

 

Diaceutics PLC

("Diaceutics" or the "Company")

 

Sale of Shares and Director/PDMR Shareholding

 

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that on 4 May 2021, Philip White, the Chief Financial Officer of Diaceutics, sold 200,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of 123 pence per Ordinary Share. The shares were sold for the purposes of settling a personal tax liability. As a result of the sale, Philip's shareholding is 1,756,389 Ordinary Shares, representing 2.09% of the Company's issued share capital.

 

 

Enquiries:

 

Diaceutics PLC

www.diaceutics.com

Peter Keeling, Chief Executive Officer

via Alma PR

Philip White, Chief Financial Officer

 

 

 

Cenkos Securities plc (Nominated adviser and broker)

+44 (0)207 397 8900

Callum Davidson / Giles Balleny

 

Michael Johnson (Sales)

 

 

 

Alma PR

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde

 

Robyn Fisher

Kieran Breheny

 

       

 

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2,500 laboratories in 51 countries. www.diaceutics.com

 

About DXRX - The Diagnostic Network®

DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.

 

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Philip White

2

Reason for notification

 

a.

Position/Status

Chief Financial Officer

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of £0.002 each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Sale of Ordinary Shares

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

123 p

200,000

 

 

 

e.

Date of the transaction

4 May 2021

f.

Place of the transaction

AIM Market of the London Stock Exchange

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEALSLEENFEFA

a d v e r t i s e m e n t